KPV Peptide: Gut Healing, Anti-Inflammatory Research, and Colitis Models

KPV (Lys-Pro-Val) is the C-terminal tripeptide fragment of alpha-melanocyte-stimulating hormone (α-MSH), the 13-amino acid POMC-derived neuropeptide. KPV retains the parent molecule's anti-inflammatory activity while showing selectivity for gut and skin — tissues with high MC3R expression.

NF-κB Suppression: The Core Mechanism

The central mechanism of KPV is inhibition of NF-κB — the master transcription factor driving TNF-α, IL-1β, IL-6, and IL-8 production. In activated macrophages and intestinal epithelial cells, KPV:

• Reduces NF-κB nuclear translocation by approximately 60-70% at physiologically relevant concentrations
• Suppresses TNF-α secretion from LPS-activated macrophages by ~50% (Catania A et al., *Annals of the New York Academy of Sciences*, 2000)
• Reduces IL-1β and IL-8 production in intestinal epithelial cell lines

IBD Models

In TNBS-induced colitis (Th1-driven, resembling Crohn's disease), KPV at 50-200 mcg/kg daily IP:

• Reduced colon shortening from 6.8 cm in controls to 8.9 cm in treated mice (vs 9.6 cm healthy)
• Decreased histological damage scores by ~50%
• Reduced myeloperoxidase activity by 43%

Oral KPV delivery was explored by Laroui H et al. (*Gastroenterology*, 2010) using PLGA nanoparticles. Orally administered KPV-NPs reduced colonic TNF-α by 72% and significantly reduced histological colitis scores — demonstrating potential for non-invasive gut-targeted delivery.

Comparison to BPC-157

BPC-157 primarily acts through angiogenesis (VEGF upregulation) and nitric oxide pathways, making it most effective for mucosal ulceration and structural gut damage. KPV, through NF-κB suppression, is more relevant for cytokine-driven inflammatory conditions (colitis, enteritis) than structural injury. In combined protocols, the two may address complementary aspects of gut pathology — inflammation (KPV) and structural repair (BPC-157).

Skin Anti-Inflammatory Activity

In mouse contact hypersensitivity models, topically applied KPV at 1 mM reduced ear swelling by ~40% and decreased skin TNF-α and IL-1β by 30-50%, positioning it as a potential research compound for inflammatory skin conditions.

KPV is a research peptide not approved for therapeutic use.

<!-- deep-links-v1 -->

Related Gut and Anti-Inflammatory Peptides

KPV occupies the anti-inflammatory gut peptide space alongside several other research compounds. Larazotide Acetate directly targets tight junction proteins to reduce intestinal permeability — a structural complement to KPV's cytokine-suppressing activity. GLP-2 (Glucagon-Like Peptide-2) promotes mucosal hyperplasia and villus growth through the GLP-2 receptor on intestinal endocrine cells, providing a proliferative counterpart to KPV's anti-inflammatory action. VIP (Vasoactive Intestinal Peptide) has broad immunomodulatory and smooth muscle regulatory actions in the GI tract that overlap with KPV in colitis models. Substance P drives neurogenic inflammation in the gut and is upregulated in IBD; understanding its antagonism contextualizes KPV's anti-inflammatory reach. Angiotensin (1-7) exerts anti-inflammatory vascular effects in the gut microvasculature relevant to colitis studies. Cartalax addresses connective tissue in the gut wall, relevant in deep-ulceration models where mucosal repair extends to the muscularis layer.